Personalized Targeted Delivery of Docetaxel Liposomes for Enhanced Cancer Treatment

A next-generation, theranostic-enabled docetaxel liposomal delivery system that leverages machine learning, 3D printing, and stimuli-responsive release mechanisms to provide personalized, adaptive, and targeted cancer therapy.

The original patent disclosed a composition of docetaxel liposomal injection with high drug loading, but it had limitations in terms of real-time monitoring, adaptive dosing, and personalized therapy. The new inventive concept addresses these limitations by integrating theranostic modules, machine learning algorithms, and stimuli-responsive release mechanisms to provide a more effective and targeted cancer treatment.

The new inventive concept consists of a system for targeted delivery of docetaxel liposomes comprising a theranostic module for real-time monitoring of tumour response and adaptive dosing. The system utilizes machine learning algorithms to predict optimal drug loading and nanoparticle size for individual patients. The liposomal composition includes a pH-sensitive polymer and a stimuli-responsive release mechanism for triggered release of the active pharmaceutical ingredient in response to tumour microenvironmental changes. The nanoparticle-based delivery system features a core-shell architecture with a biodegradable polymer core and a lipid bilayer shell for enhanced circulation time and tumour penetration. The modular platform enables the development of personalized docetaxel liposomal formulations using 3D printing and artificial intelligence-driven design optimization.

The new claims introduce the concept of theranostic modules, machine learning algorithms, and stimuli-responsive release mechanisms, which are not present in the original patent. These novel features provide a paradigm shift in docetaxel liposomal delivery, enabling real-time monitoring, adaptive dosing, and personalized therapy.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, various stimuli-responsive release mechanisms, or alternative nanoparticle architectures. Additionally, the modular platform could be adapted for the development of personalized formulations for other cancer treatments.

The new inventive concept has significant commercial potential in the oncology market, particularly in the area of personalized cancer therapy. The integration of theranostic modules, machine learning algorithms, and stimuli-responsive release mechanisms could provide a competitive advantage in the market, enabling targeted and adaptive cancer treatment.